Vasostatin-Apo2L, a preclinical product being developed by company’s Shanghai Qiaer subsidiary, is a recombinant fusion protein that integrates the function of extracted fragments of vasostatin, an inhibitor of angiogenesis and tumor growth, with the function of Rh-Apo2L, which induces the apoptosis of cancer cells. It has shown positive results in the lab. Aida’s researchers believe that the integration of vasostatin-Apo2L will have higher efficacy in certain cancer treatments than currently prescribed methods.
Vasostatin-Apo2L is developed by the same research team that created Rh-Apo2L. Rh-Apo2L has successfully completed its Phase II clinical testing and is going to file application with the PRC government’s State FDA to start the Phase III trials. The development of vasostatin-Apo2L will benefit strongly from the experience garnered in the research, manufacturing and distribution of Rh-Apo2L.